Efficacy and safety of anlotinib plus EGFR-TKI for advanced non-small cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials
Compared with EGFR-TKI monotherapy, anlotinib plus EGFR-TKI provides some clinical benefits for patients with advanced NSCLC harboring EGFR mutations, but it does not significantly improve long-term survival and has higher toxicity.
Authors
- Dailong Li (ORCID: https://orcid.org/0000-0002-0644-4791)
- Yuan Che
- Chunlai Cheng
- Xiaoxi Zhang (ORCID: https://orcid.org/0000-0002-7071-5285)
- Yali Xiong
- Yuan Du (ORCID: https://orcid.org/0009-0000-2144-6392)
Publication Details
- Journal
- Medicine
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1097/md.0000000000045654
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00